Position in ABEO
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$7,663,638
+$2,003,109 QoQ
Shares Held
1,240,071
-1.9% QoQ
Ownership
2.17%
of shares outstanding
% of Portfolio
0.14%
of 13F equity value
Holder Rank
#9
of 125 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ABEO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026KENNEDY CAPITAL MANAGEMENT LLC holds $451,584,893 across 62 Biotechnology names. ABEO ranks #24 (1.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HALO |
Halozyme Therapeutics, Inc.
|
544,994 | $42,656,680 | |
| 2 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
193,215 | $21,452,661 | |
| 3 | NRIX |
Nurix Therapeutics, Inc.
|
724,508 | $17,576,564 | |
| 4 | CORT |
Corcept Therapeutics Inc
|
201,979 | $17,562,074 | |
| 5 | PTGX |
Protagonist Therapeutics, Inc
|
134,019 | $16,428,049 | |
| 6 | MGTX |
MeiraGTx Holdings plc
|
1,105,421 | $14,934,237 | |
| 7 | ADMA |
Adma Biologics, Inc.
|
1,755,152 | $14,690,622 | |
| 8 | NAMS |
NewAmsterdam Pharma Co N.V.
|
421,374 | $14,280,364 |
All Filings in ABEO
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7,663,638 | 1,240,071 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $5,660,529 | 1,263,511 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $5,534,000 | 1,050,095 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $5,548,556 | 1,050,863 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $3,816,977 | 672,003 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $2,959,591 | 621,763 | Shares | Sole | 2025-05-13 | |
| No filing history on record for this holder in this stock. | ||||||